![Matt Cahill](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Matt Cahill
Directeur des opérations chez Qu Biologics, Inc.
Profil
Matt Cahill is currently the Chief Operating Officer at Qu Biologics, Inc. He previously worked as the Head of Business Operations and Director at Deep Genomics, Inc. Dr. Cahill holds a doctorate from the University of Cambridge and graduate and MBA degrees from the University of Toronto.
Postes actifs de Matt Cahill
Sociétés | Poste | Début |
---|---|---|
Qu Biologics, Inc.
![]() Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Directeur des opérations | 23/01/2023 |
Anciens postes connus de Matt Cahill
Sociétés | Poste | Fin |
---|---|---|
Deep Genomics, Inc.
![]() Deep Genomics, Inc. BiotechnologyHealth Technology Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada. | Directeur des opérations | - |
Formation de Matt Cahill
University of Cambridge | Doctorate Degree |
University of Toronto | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Deep Genomics, Inc.
![]() Deep Genomics, Inc. BiotechnologyHealth Technology Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada. | Health Technology |
Qu Biologics, Inc.
![]() Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Health Technology |